publication date: Oct. 4, 2019

NCI Trials

NCI Trials for October

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. 

For further information, contact the principal investigator listed.

 

Phase I – ABTC-1804

Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas

Adult Brain Tumor Consortium

Grossman, Stuart Alan

(410) 955-8837

 

Phase II – ACNS1723

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Children’s Oncology Group

Lulla, Rishi Ramesh

(401) 444-5171

 

Phase III – A221803

Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial

Alliance for Clinical Trials in Oncology

Corbin, Kimberly S.

(507) 284-2669

 

Phase Other – WF-1805CD

Implementation and Effectiveness Trial of HN-STAR

Wake Forest NCORP Research Base

Weaver, Kathryn E.

(336) 713-5062

Copyright (c) 2019 The Cancer Letter Inc.